Harvard Business Review names Pascal Soriot among ‘Best Performing Top 100 CEOs in the World’ 2019

The Harvard Business Review (HBR) has selected Pascal Soriot among the Top 100 Best Performing CEOs in the world for 2019, and one of only three CEOs from a biopharmaceutical company. The ranking features this month, in the November print edition of HBR.

HBR's ranking is based on a CEO’s financial performance as well as environmental, social, and governance (ESG) ratings. Unlike rankings that are based on subjective evaluations or short-term metrics, the CEO 100 list relies on objective performance measures over a chief executive’s entire tenure, according to HBR.

AstraZeneca posted its first full year of sustainable growth last year, the first since 2009, and is now on a rapid growth trajectory driven by an emerging pipeline that includes five new medicines that will reach blockbuster status this year. The company’s emphasis on following the science and patient-centric focus continues to drive innovation and underpins its sales performance across its three therapy areas – oncology, cardiovascular, renal and metabolism, and respiratory – and across all its major markets including in the US, Europe and China.

Pascal Soriot, Chief Executive Officer, said:

This recognition goes to the more than 60,000 AstraZeneca employees who come to work every day to follow the science and transform medicine. It speaks volumes about the commitment of our people to bring innovative medicines to patients whether they work in our labs, in the field, our manufacturing sites or our many other locations around the world.

Leif Johansson, Chairman of the Board of AstraZeneca, said: 

Pascal’s leadership and strategic thinking have been instrumental in transforming AstraZeneca in recent years. This award reflects not only his dedication, expertise and integrity but also that of the many thousands of colleagues across AstraZeneca who have delivered exceptional results for the millions of patients we serve around the world. It is a great honour to see AstraZeneca recognised for its work in one of the world’s most respected publications.

Pascal Soriot is ranked number 77 out of 100 CEOs in the HBR report which can be found here online: HBR – The CEO 100, 2019 Edition.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.



Media Relations



Gonzalo Viña


+44 203 749 5916

Rob Skelding


+44 203 749 5821

Rebecca Einhorn


+1 301 518 4122

Matt Kent


+44 203 749 5906

Jennifer Hursit


+44 203 749 5762

Christina Malmberg Hägerstrand


+46 8 552 53 106

Michele Meixell


+1 302 885 2677


Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler


+44 203 749 5797

Christer Gruvris

BioPharmaceuticals (CV, Metabolism)

+44 203 749 5711

Nick Stone

BioPharmaceuticals (Renal), ESG

+44 203 749 5716

Josie Afolabi

BioPharmaceuticals (Respiratory),

other medicines

+44 203 749 5631

Craig Marks

Finance, fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access, retail investors

+44 203 749 5824

US toll-free


+1 866 381 72 77



  • Corporate and financial